The penetration of imipenem/cilastatin into ascitic fluid in patients with chronic liver disease.
Rolando
N
N
Institute of Liver Studies, King's College School of Medicine and Dentistry, London, UK.
Wade
J J
JJ
Philpott-Howard
J N
JN
Casewell
M W
MW
Williams
R
R
D000328:Adult; D000900:Anti-Bacterial Agents / Q000097:blood / Q000493:pharmacokinetics*; D001202:Ascitic Fluid / Q000378:metabolism* / Q000382:microbiology; D002908:Chronic Disease; D015377:Cilastatin / Q000097:blood / Q000493:pharmacokinetics*; D000077728:Cilastatin, Imipenem Drug Combination; D004338:Drug Combinations; D005260:Female; D006207:Half-Life; D006801:Humans; D015378:Imipenem / Q000097:blood / Q000493:pharmacokinetics*; D008107:Liver Diseases / Q000378:metabolism*; D008297:Male; D008875:Middle Aged
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D015377:Cilastatin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination